Retatrutide Triumph-1 Trial Results Explained
Retatrutide's Triumph-1 phase 3 trial produced an average 25% body weight loss at the highest dose over 80 weeks, with some lean mass loss that tracks in line with other obesity drugs rather than exceeding it. Preserving muscle depends on resistance training and adequate protein, not the drug itself.